Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/6144

Title: Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced Fallopian tube carcinoma: an EORTC Gynecological Cancer Group Study
Authors: Wagenaar, H.C.
Pecorelli, S.
Vergote, I.
CURRAN, Desmond
Wagener, D.J.Th.
Kobierska, A.
Bolis, G.
ten Bokkel Huinink, W.
Lacave, A.J.
Madronal, C.
Forni, M.
de Oliveira, C.F.
Mangioni, C.
Nooij, M.A.
Goupil, A.
Kerbrat, P.
Marth, Ch.
Tumolo, S.
Herben, M.G.
Zanaboni, F.
Vermorken, J.B.
Issue Date: 2001
Publisher: I R O G CANADA
Citation: European journal of gynaecological oncology, 22(3). p. 187-193
Abstract: Objective: To investigate the clinical activity and toxicity of a combination chemotherapy consisting of cyclophosphamide (C), adriamycin (A) and cisplatin (P) for patients with primary adenocarcinoma of the Fallopian tube having FIGO stage III-IV disease. Methods: The CAP-regimen consisted of cyclophosphamide 600 mg/m2, adriamycin 45 mg/m2, and cisplatin 50 mg/m2 administered intravenously on day one every 28 days. Results: Twenty-four eligible patients with histologically-confirmed Fallopian tube adenocarcinoma were entered in the trial. Fourteen patients had FIGO stage III and ten had stage IV disease. The median number of CAP cycle was six. Ten patients had a complete and six had a partial response (response rate 67%, 95% confidence limits: 45%-84%). WHO-grade III-IV side-effects included haematological toxicity, nausea/vomiting and alopecia. Furthermore, mild signs of cisplatin-related peripheral neurotoxicity were observed. At a median follow-up of 40 months, nine patients were alive and 15 had died due to malignant disease. The median time to progression was 13 months for all patients. The median overall survival was 24 months and the 1-, 3- and 5-year survival and their 95% confidence limits were 73% (54-92%), 25% (4-46%) and 19% (0-38%), respectively. Conclusion: The present data confirm the therapeutic activity of the CAP-regimen in primary Fallopian tube adenocarcinoma. The response rate is moderate and the toxicity profile is acceptable.
URI: http://hdl.handle.net/1942/6144
ISI #: 000170205400004
ISSN: 0392-2936
Category: A1
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.